June 22, 2020
Saying the case record has "changed significantly," Alere told the Patent Trial and Appeal Board on Monday that it's not bound by a 2018 decision upholding three of four claims in a Rembrandt Diagnostics urine testing patent, and the board should reconsider their patentability on remand.